Latest Commercial Readiness News

Page 1 of 11
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Provaris Energy has accepted $914,500 in final Share Purchase Plan applications after delayed electronic transfers pushed demand 50% above its $600,000 target. The raise will fund hydrogen and LCO₂ development, while a proposed option package still requires shareholder approval.
Maxwell Dee
Maxwell Dee
21 Oct 2026
Provaris Energy’s share purchase plan attracted preliminary applications of $755,000, exceeding its $600,000 target. The company will accept the oversubscription, with the final amount, issue price and share allocation due on 21 October.
Maxwell Dee
Maxwell Dee
19 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.
Sophie Babbage
Sophie Babbage
30 Sept 2026
FirstWave Cloud Technology has lodged a provisional patent for an AI-driven network monitoring system that promises automated, explainable root cause diagnosis, aiming to boost its fastest-growing revenue stream.
Sophie Babbage
Sophie Babbage
4 Sept 2026
Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.
Ada Torres
Ada Torres
28 Aug 2026
Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
Ada Torres
Ada Torres
27 Aug 2026
Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.
Victor Sage
Victor Sage
25 Aug 2026
Viridis Mining and Minerals completes a Definitive Feasibility Study for its Colossus Rare Earth Project, confirming strong economics and project readiness, while securing $120 million in equity funding to advance into execution.
Maxwell Dee
Maxwell Dee
20 Aug 2026
Podium Minerals has secured a $4 million underwritten share purchase plan to fund advancing metallurgical work and site rehabilitation at its Parks Reef PGM Project, following a significant step-change in concentrator performance.
Maxwell Dee
Maxwell Dee
13 Aug 2026
Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.
Ada Torres
Ada Torres
31 July 2026

Browse the archive

Full archive